Posts

Roche sees receding biosimilar impact, but Vabysmo slump returns

on

Trump floats countdown to 200% tariffs on generic drugs imported to US

on

There is always a first: Why US biotech Axiom will begin its IPO journey in Hong Kong

on

Bipartisan Senate bill seeks to build vigilance around foreign companies making drugs in US

on

Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

on

US Physicians Cautious About AI‑Driven Home Testing

on

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

on

Recent US moves add hurdles to US investments in China biotech

on

Independent expert group to review HPV vaccine evidence after US recommendation change

on

AstraZeneca appoints Rick R. Suarez to lead U.S. BioPharmaceuticals business and $50B investment drive

on

Independent expert group to review HPV vaccine evidence after US recommendation change

on

AstraZeneca appoints Rick R. Suarez to lead U.S. BioPharmaceuticals business and $50B investment drive

on

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

on

US Commits $480-487 Million in Health Funding to Ivory Coast Under 'America First' Health Strategy

on

White House unveils nine new “most-favored-nation” drug pricing deals

on

AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge

on

US-Backed Group Reports Success with New Tuberculosis Treatment in Phase 2 Study

on

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

on

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact

on

Drugmakers Push US Expansion After Trump’s 100% Pharma Tariff Threat

on